Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them. Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

In this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer. Visit www.morningcommutepodcast.com/HER3Agnostic2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar. Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

In this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer. Visit www.morningcommutepodcast.com/HRPositiveBreast3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

In this podcast, our faculty take a look at some of the clinical data behind the newer treatment strategies for HR-positive breast cancer as well as how to address and manage some associated adverse events. Visit www.morningcommutepodcast.com/HRPositiveBreast2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

In this podcast, our faculty discuss some newer treatment approaches for patients with HR-positive breast cancer including PI3K inhibition, AKT inhibition, and oral selective estrogen receptor down regulators. Visit www.morningcommutepodcast.com/HRPositiveBreast1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial.  Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

In this podcast our faculty discuss the latest treatment options for AML that target FLT3 mutations: midostaurin, gilteritinib, and the new kid on the block, quizartinib. Visit www.morningcommutepodcast.com/aml2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

Our faculty discuss the importance of biomarker testing for FLT3 and FLT3-ITD and the prognostic impact for these patients, especially now that there are therapies targeting these mutations. Visit www.morningcommutepodcast.com/aml1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more

In this episode of our three-part series on endometrial cancer, our faculty continue their discussion by turning to some of the ongoing, and some may say groundbreaking, clinical trials for the use of immunotherapies in the first-line setting. Visit www.MorningCommutePodcast.com/Endometrial4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit ..read more